Friday, October 30, 2026

58% of AP Teams Skip Fraud Checks Due to Time Pressure, Creating $41B Annual Loss Risk

Manual accounts payable verification fails 58% of the time as processors skip fraud checks under time constraints, PYMNTS data shows. Companies lose $41 billion annually to AP fraud while AI-driven verification systems process payments 3x faster with 100% check completion. The gap between manual shortcuts and automated controls is reshaping corporate compliance strategies.

58% of AP Teams Skip Fraud Checks Due to Time Pressure, Creating $41B Annual Loss Risk
Image generated by AI for illustrative purposes. Not actual footage or photography from the reported events.

58% of accounts payable professionals admit to skipping verification steps at least occasionally due to time constraints, according to PYMNTS research. This manual verification failure rate translates to $41 billion in annual corporate fraud losses across U.S. businesses.

Time pressure drives the problem. AP teams face 15-30 invoice verifications daily per processor. Manual checks require 8-12 minutes per invoice for vendor validation, duplicate detection, and approval workflows. Under deadline pressure, verification steps get cut.

AI-automated verification eliminates the speed-accuracy tradeoff. Systems process invoices in 2-4 minutes while completing 100% of fraud checks. Pelican Canada Inc., with 25 years in AI-driven payment processing, reports zero verification skips across clients processing 500,000+ monthly transactions.

"Production-ready AI strategy relies on data quality," says Peter Cavicchia, payment processing expert. Clean vendor databases and transaction histories train AI models to flag anomalies humans miss under time pressure.

The verification gap creates three systemic risks. First, duplicate payments slip through when processors skip cross-reference checks. Second, fraudulent vendor account changes bypass approval workflows. Third, invoice manipulation goes undetected without amount verification against purchase orders.

Manual AP departments show fraud detection rates of 67% compared to 94% for AI-assisted teams, industry benchmarks indicate. The 27-point gap costs mid-market companies $180,000-$320,000 annually in undetected fraud.

Processing speed compounds with scale. Companies handling 10,000+ monthly invoices cannot maintain manual verification coverage. AI systems scale linearly—processing 100,000 invoices requires the same per-transaction time as 1,000.

Compliance teams face pressure to eliminate verification shortcuts. Sarbanes-Oxley internal control requirements mandate consistent AP processes. The 58% skip rate creates audit findings and control weakness disclosures.

Implementation requires data preparation. AI models need 6-12 months of clean transaction history for training. Vendor master file cleanup precedes deployment. Companies with poor data governance delay AI adoption 8-14 months.

The business case strengthens as fraud losses rise. AP fraud increased 23% year-over-year in 2025. Manual verification shortcuts accelerate losses while AI costs drop below $2 per transaction processed.

What we know · the intelligence behind this page
Live from the substrate
What we're seeing
ESMO 2026 Oncology Data Wave Builds Toward Ivonescimab PDUFA, While Micro-Cap Biotech Exits the Market
Late October 2026 is a dense catalyst window led by ESMO 2026. Daiichi Sankyo's DXd antibody-drug conjugate (ADC) programs (DESTINY-Lung04, DESTINY-Breast11, REJOICE-Ovarian01/02, TUXEDO-3), Guardant's 25 abstracts and the PACE-LUNG ctDNA trial all report there. These feed into the FDA's 14 November 2026 PDUFA date for ivonescimab. Large and mid-cap developers with late-stage data and commercial launches (ZEGFROVY, ANKTIVA, MIUDELLA, lorundrostat, duvakitug) are drawing capital and attention. Spago Nanomedical's board decision to seek a Nasdaq First North delisting (EGM 19 November, application 25 January 2027) shows the capital squeeze on early-stage, single-asset names (Tumorad is Phase I).
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
Ford Motor Company
Both facts give cash for Ford Motor Company at the same point in time (2025-12-31; FY 2025 year-end and Q4 2025 year-end are the same date). Both are labelled USD, but the values are 23,356,000,000 and 23.356, which cannot both be true in USD. The two numbers agree once the second is read as billions (23.356 bn = 23,356,000,000), so the economic content is consistent and the conflict is a unit/scale error in the Q4 2025 record. The period is not the reason for the conflict: a Q4 and an FY figure at the same year-end date should match.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,994
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,994 facts checked against source5,503 source documents archived
Query this data → isubstrate.com